Arrowhead Research
ARWR
$74.30
+4.10%
Arrowhead Pharmaceuticals Inc. is a commercial-stage biotechnology company developing RNA interference (RNAi) therapies for diseases driven by genetic abnormalities or protein overproduction. It distinguishes itself as a leader in targeted RNAi delivery, with a pipeline spanning cardiometabolic, neuromuscular, pulmonary, and liver indications. The current investor narrative centers on the company's transition to a commercial-stage entity, with recent revenue volatility tied to milestone payments and partnership deals, while the market debates the sustainability of its growth trajectory amid pipeline progress and regulatory milestones.…
ARWR
Arrowhead Research
$74.30
Related headlines
ARWR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arrowhead Research's 12-month outlook, with a consensus price target around $91.25 and implied upside of +22.8% versus the current price.
Average Target
$91.25
0 analysts
Implied Upside
+22.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$46 - $110
Analyst target range
Arrowhead is covered by 12 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.46 on a 1-5 scale, where 1 is Strong Buy). The average target price is $91.25, implying approximately +27.1% upside from the current price of $71.82. The distribution leans heavily bullish, with no sell ratings and only a few hold-equivalent ratings (Market Perform). The target price range spans from a low of $46.00 to a high of $110.00. The high target of $110 assumes successful pipeline advancement and potential commercial launches, driving significant revenue growth and multiple expansion. The low target of $46.00 prices in risks such as clinical trial failures, regulatory delays, or continued revenue volatility. Recent ratings actions show upgrades: Morgan Stanley upgraded from Equal Weight to Overweight in April 2026, while HC Wainwright, Chardan, and B. Riley maintain Buy ratings. The relatively wide spread between low and high targets ($64) signals high uncertainty around the timing and magnitude of future catalysts, but the strong buy consensus reflects confidence in the company's long-term RNAi platform potential.
Bulls vs Bears: ARWR Investment Factors
Arrowhead Pharmaceuticals presents a high-risk, high-reward opportunity. The bull case is anchored by a strong buy analyst consensus, a robust balance sheet, and a compelling forward P/S discount to peers, supported by a 307% one-year price surge that reflects confidence in its RNAi platform. However, the bear case highlights extreme revenue volatility, ongoing net losses, and a wide target range that underscores binary risk tied to pipeline milestones. The single most important tension is whether the company can convert its pipeline progress into sustainable, recurring revenue—if it does, the stock could re-rate significantly; if not, the current valuation may prove unsustainable. Currently, the bull case has stronger evidence given the analyst consensus and balance sheet strength, but the risk of near-term volatility remains high.
Bullish
- Strong Buy Analyst Consensus: 12 analysts rate ARWR a Strong Buy (mean 1.46/5), with an average target of $91.25 implying 27.1% upside from $71.82. The high target of $110 suggests potential for 53% upside, reflecting confidence in pipeline catalysts.
- Powerful Long-Term Price Momentum: ARWR has surged 307.4% over the past year, vastly outperforming the S&P 500's 20.9% gain. The stock's relative strength of +286.5% over one year indicates strong investor conviction in the RNAi platform and commercial transition.
- Robust Balance Sheet with Low Debt: Current ratio of 4.86 and debt-to-equity of 0.79 indicate ample liquidity and manageable leverage. Cash of $188.5M provides runway for operations without near-term financing risk, supporting pipeline development.
- Attractive Forward Valuation: Forward P/S of 2.90x is a deep discount to the biotech industry average of 8-10x. This implies the market is not fully pricing in expected revenue growth to $1.59B, offering upside if milestones are achieved.
Bearish
- Extreme Revenue Volatility: Quarterly revenue swung from $542.7M (Q2 FY2025) to $73.7M (Q2 FY2026), an 86.4% YoY decline. This lumpiness, driven by episodic milestone payments, makes earnings unpredictable and complicates valuation.
- Negative Trailing Net Income: TTM net loss of $132.7M and negative net margin of -1.8% highlight ongoing unprofitability. While profitability is achievable with milestones, the core business remains loss-making, raising concerns about sustainability.
- High Valuation Uncertainty: The wide analyst target range ($46-$110) reflects significant uncertainty. The low target implies 36% downside from current levels, and the stock's beta of 1.265 amplifies market volatility, adding risk.
- Recent Price Momentum Divergence: Despite a 307% one-year gain, the stock has declined 6.9% in the past month and 9% in the last trading day. This short-term weakness may signal profit-taking or fading momentum, increasing near-term downside risk.
ARWR Technical Analysis
Arrowhead's stock has exhibited a powerful sustained uptrend over the past year, with a 1-year price change of +307.4%. The current price of $71.82 sits at 81.8% of its 52-week range ($14.30–$87.83), indicating the stock is trading near the upper end of its range, reflecting strong momentum but also potential overextension. This positioning suggests the market is pricing in continued positive catalysts, though the proximity to the 52-week high of $87.83 introduces resistance risk. Short-term momentum has diverged from the longer-term trend, with a 1-month price change of -6.9% contrasting sharply with the 1-year gain. The 3-month change of +5.6% shows deceleration from the 6-month change of +12.5%, indicating a loss of near-term upside momentum. This divergence could signal a temporary pullback or consolidation phase within the broader uptrend, rather than a trend reversal, given the stock's relative strength versus the S&P 500 (1-year relative strength of +286.5%). The 52-week low of $14.30 provides a major support level, while the 52-week high of $87.83 acts as key resistance. A breakout above $87.83 would signal a continuation of the uptrend, potentially targeting new highs, while a breakdown below the recent low of $55.01 (from March 2026) could indicate a deeper correction. With a beta of 1.265, Arrowhead is 26.5% more volatile than the S&P 500, meaning it amplifies market moves—a factor that warrants careful position sizing.
Beta
1.26
1.26x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$14-$88
Price range past year
Annual Return
+294.2%
Cumulative gain past year
| Period | ARWR Return | S&P 500 |
|---|---|---|
| 1m | -8.3% | +0.3% |
| 3m | +6.9% | +4.7% |
| 6m | +16.4% | +7.5% |
| 1y | +294.2% | +18.4% |
| ytd | +9.6% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ARWR Fundamental Analysis
Arrowhead's revenue trajectory is highly volatile, driven by episodic partnership and milestone payments. In the most recent quarter (Q2 FY2026, ended March 31, 2026), revenue plunged 86.4% year-over-year to $73.7 million, following a massive $264.0 million in Q1 FY2026 and $542.7 million in Q2 FY2025. This lumpiness reflects the company's reliance on collaboration revenues rather than steady product sales, making the growth trend difficult to assess on a quarterly basis. The company is currently unprofitable on a trailing basis, with a net loss of $132.7 million in Q2 FY2026 and a net margin of -1.8% over the trailing twelve months. Gross margin remains at 100% due to zero cost of revenue, but operating expenses—particularly R&D ($173.3 million in Q2)—drive significant losses. However, the company achieved positive net income of $30.8 million in Q1 FY2026 and $370.4 million in Q2 FY2025, demonstrating that profitability is achievable when milestone payments are recognized. Arrowhead maintains a strong balance sheet with a current ratio of 4.86 and a debt-to-equity ratio of 0.79, indicating ample liquidity and manageable leverage. Free cash flow was positive $81.9 million in Q2 FY2026, though the trailing twelve-month free cash flow is -$50.9 million, reflecting the lumpy nature of cash generation. The company's ability to fund operations without relying on external financing is supported by its cash position of $188.5 million as of March 31, 2026.
Quarterly Revenue
$73737000.0B
2026-03
Revenue YoY Growth
-86.4%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$-50872000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ARWR Overvalued?
Given that Arrowhead's trailing net income is negative (TTM net income of -$132.7 million), the P/E ratio is not meaningful. Therefore, we lead with the price-to-sales (P/S) ratio. The trailing P/S ratio is 5.56x, while the forward P/S (based on estimated revenue of $1.59 billion) is approximately 2.90x. The gap between trailing and forward P/S implies the market expects significant revenue growth, likely driven by new partnerships or product approvals. Compared to the biotechnology industry average P/S of roughly 8-10x, Arrowhead's trailing P/S of 5.56x appears at a discount. However, the forward P/S of 2.90x suggests an even deeper discount relative to peers, potentially reflecting the market's skepticism about the sustainability of revenue spikes or the risk of pipeline setbacks. Historically, Arrowhead's P/S ratio has ranged from near 0x (in quarters with zero revenue) to over 900x (in low-revenue periods). The current trailing P/S of 5.56x is near the lower end of its historical range, which could indicate a value opportunity if revenue growth materializes, but it also reflects the inherent lumpiness of its revenue model.
PE
-2827.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Arrowhead's financial profile is dominated by extreme revenue volatility, with quarterly revenue swinging from $542.7M to $73.7M (86.4% decline) due to episodic milestone payments. The company is unprofitable on a trailing basis, with a TTM net loss of $132.7M and a net margin of -1.8%. While the balance sheet is strong (current ratio 4.86, debt-to-equity 0.79), the reliance on partnership revenues means any delay in milestones could quickly deplete cash reserves. The $188.5M cash position provides a cushion, but the negative TTM free cash flow of -$50.9M indicates that the company is not yet self-sustaining.
Market & Competitive Risks: The stock's beta of 1.265 makes it 26.5% more volatile than the market, amplifying downside during selloffs. The wide analyst target range ($46-$110) reflects high uncertainty, and the stock trades near the top of its 52-week range (81.8% of high), leaving limited upside if catalysts disappoint. Competitive risks include other RNAi players like Alnylam and CRISPR Therapeutics, as well as traditional biotechs targeting similar indications. Regulatory headwinds could delay approvals, and the recent 6.9% monthly decline suggests fading momentum.
Worst-Case Scenario: A clinical trial failure or regulatory rejection for a key pipeline asset could trigger a sharp selloff. In such a scenario, the stock could fall to the analyst low target of $46.00, representing a 36% decline from the current price of $71.82. The 52-week low of $14.30 is a more extreme downside, implying an 80% loss, but that level is unlikely unless the company faces a fundamental business collapse. A more realistic worst case is a 30-40% drawdown to the $40-50 range, consistent with the stock's historical max drawdown of -24.64% and the low analyst target.